Merck director discusses company's strategies for clinical research success

November 2007
Clinical Trials Administrator;Nov2007, Vol. 5 Issue 11, p125
This article presents an interview with Ernesto Aycardi, senior director at Merck & Co., about the company's strategies for clinical research success. The interview begins with the complexity in the drug development process. Aycardi then discusses the relations of Merck with researchers, regulatory agencies and medical societies. In addition, Aycardi talks about some ways that Merck has improved collaboration with clinical trial sites.


Related Articles

  • A MERCK IN PROGRESS. Armstrong, Walter; Donahue, Marylyn // Pharmaceutical Executive;Sep2007, Vol. 27 Issue 9, p62 

    An interview with the head of the new experimental-medicine division of the Merck & Co. Inc., Gary Herman is presented. When asked about when was the time he realized that the old way of doing reseach and development was no longer working and needed to be fixed, he refer to their Januvia...

  • Bad seed? Critics say drug study more marketing than medicine.  // IRB Advisor;Nov2008, Vol. 8 Issue 11, p121 

    The article discusses the Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness (ADVANTAGE). It is suspected to be a seeding trial but Merck denied it by emphasizing the purpose of examining Vioxx. A seeding trial refers to a clinical...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;Nov2008, Vol. 7 Issue 11, p22 

    The article offers news briefs related to infectious diseases. Napo Pharmaceuticals Inc. has revealed positive data for the efficacy of crofelemerin treating cholera patients. FDA has approved Merck & Co.s Gardasil.vaccine for the prevention of vaginal and vulvar cancer. Novartis AG affirmed...

  • Calif. Accelerator Launches With $90M Funding from Merck. Shaffer, Catherine // BioWorld Today;3/16/2012, Vol. 23 Issue 42, p1 

    The article reports on the launching of California Institute for Biomedical Research (Calibr), a new nonprofit translational institute by Merck & Co. Inc. to accelerate translation of basic biomedical research into commercialized medicines. A funding valued at 90 million U.S. dollars will be...

  • Tadataka Yamada.  // Nature Reviews Drug Discovery;Dec2007, Vol. 6 Issue 12, p950 

    An interview with Tadataka Yamada, president of the Global Health program at the Bill & Melinda Gates Foundation. When asked about the to give examples of successes that the Gates Foundation has had in promoting the discovery and development of drugs for neglected diseases, he states that it...

  • Pharmaceuticals in brief.  // Chemical Market Reporter;7/25/2005, Vol. 268 Issue 3, p22 

    The article presents news related to the pharmaceutical industry. Organon has signed to use Genaissance Pharmaceuticals lnc.'s HAP technology for pharmacogenetic research in clinical trials, specifically focusing on the HPA stress axis for the treatment of psychiatric disorders. Merck & Co. Inc....

  • Research Update.  // PharmaWatch: Biotechnology;Feb2005, Vol. 4 Issue 2, p4 

    The article offers global news briefs. GloxoSmithKline has conducted phase II clinical trial of an anti-cancer drug to determine its safety in treating patients with advanced ovarian cancer. Vertex Pharmaceuticals Inc. has increased its market share after facilitating a phase 1 clinical study...

  • Boceprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p203 

    Boceprevir (SCH 503034; SCH-503034) is a peptidomimetic NS3/4A serine protease inhibitor, representing a new class of hepatitis C virus (HCV) inhibitors. It is being developed by Merck & Co. as part of a combination therapy regimen for the treatment of HCV infections. In two phase III trials,...

  • Opinion: Merck & Co.: enters into R&D partnership with Ranbaxy.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 6, p28 

    The article focuses on the joint venture between pharmaceutical companies Merck &Co. Inc. and Ranbaxy Ltd. which aims to develop antibacterial and antifungal drugs. Ranbaxy will get $100 million for each drug and be in charge of developing the drugs up to Phase IIa testing while Merck will...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics